Michaël Desjardins

Michaël Desjardins

Auto-generated profile, based on publicly available information

Michaël Desjardins

Département de microbiologie, infectiologie et immunologie, Faculté de médecine, Université de Montréal , Montréal, Québec

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
DFDean Follmann
Dean Follmann
HJHolly Janes
Holly Janes
OBOlive D. Buhule
Olive D. Buhule
HZHonghong Zhou
Honghong Zhou
BGBethany Girard
Bethany Girard
LBLindsey R. Baden
Lindsey R. Baden
Antinucleocapsid antibodies (anti-N Abs) are currently being used to diagnose prior SARS-CoV-2 infection in individuals and to determine community seroprevalence of SARS-CoV-2. In a large, randomiz... Visual Antinucleocapsid Antibodies After SARS-CoV-2 Infection in COVE. Antinucleocapsid antibodies (anti-N Abs) are currently being used to diagnose prior SARS-CoV-2 infection in individua... Background: Immunoassays for determining past SARS-CoV-2 infection have not been systematically evaluated in vaccinated persons in comparison with unvaccinated persons. Objective: To evaluate antin...

15 September 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
MCMdcm Matthew P. Cheng
Mdcm Matthew P. Cheng
CYCedric P. Yansouni
Cedric P. Yansouni
NBNicole E. Basta
Nicole E. Basta
MDMichaël Desjardins
Michaël Desjardins
SKSanjat Kanjilal
Sanjat Kanjilal
JPJesse Papenburg
Jesse Papenburg
Accurate serologic tests to detect host antibodies to SARS-CoV-2 will be critical for the public health response to the COVID-19 pandemic. This article discusses key use cases for SARS-CoV-2 antibo... Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2) will be critical for the public health response to the coronavirus disease...

28 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
KAKaren Aymonnier
Karen Aymonnier
JNJulie Ng
Julie Ng
LFLaura E. Fredenburgh
Laura E. Fredenburgh
KZKatherin Zambrano-Vera
Katherin Zambrano-Vera
PMPatrick Münzer
Patrick Münzer
DWDenisa Wagner
Denisa Wagner
Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) engages the inflammasome in monocytes and macrophages and leads to the cytokine storm in COVID-19. Neutrophils, the most abundant leukocytes, release neutrophil extracellular traps (NETs), which have been implicated in the pathogenesis of COVID-19. Our recent study shows that activation of the NLRP3 inflammasome is important for NET release in sterile inflammation. However, the role of neutrophil inflammasome formation in human disease is unknown. We hypothesized that SARS-CoV-2 infection may induce inflammasome activation in neutrophils. We also aimed to assess the localization of inflammasome formation (ie, apoptosis-associated speck-like protein containing a CARD [ASC] speck assembly) and timing relative to NETosis in stimulated neutrophils by real-time video microscopy. Neutrophils isolated from severe COVID-19 patients demonstrated that ∼2% of neutrophils in both the peripheral blood and tracheal aspirates presented ASC speck. ASC speck was observed in neutrophils with an intact poly-lobulated nucleus, suggesting early formation during neutrophil activation. Additionally, 40% of nuclei were positive for citrullinated histone H3, and there was a significant correlation between speck formation and nuclear histone citrullination. Time-lapse microscopy in lipopolysaccharide -stimulated neutrophils from fluorescent ASC reporter mice showed that ASC speck formed transiently and at the microtubule organizing center long before NET release. Our study shows that ASC speck is present in neutrophils from COVID-19 patients with respiratory failure and that it forms early in NETosis. Our findings suggest that inhibition of neutrophil inflammasomes may be beneficial in COVID-19.

21 January 2022 in Science
Verified
Journal Article
Open access
KNKatherine G. Nabel
Katherine G. Nabel
SCSarah A. Clark
Sarah A. Clark
SSSundaresh Shankar
Sundaresh Shankar
JPJunhua Pan
Junhua Pan
LCLars E. Clark
Lars E. Clark
JAJonathan Abraham
Jonathan Abraham
Many studies have examined the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants on neutralizing antibody activity after they have become dominant strains. Here, we evaluate the consequences of further viral evolution. We demonstrate mechanisms through which the SARS-CoV-2 receptor binding domain (RBD) can tolerate large numbers of simultaneous antibody escape mutations and show that pseudotypes containing up to seven mutations, as opposed to the one to three found in previously studied variants of concern, are more resistant to neutralization by therapeutic antibodies and serum from vaccine recipients. We identify an antibody that binds the RBD core to neutralize pseudotypes for all tested variants but show that the RBD can acquire an N-linked glycan to escape neutralization. Our findings portend continued emergence of escape variants as SARS-CoV-2 adapts to humans.

13 August 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
JCJennifer L. Crombie
Jennifer L. Crombie
ASAmy C. Sherman
Amy C. Sherman
CCChi-An Cheng
Chi-An Cheng
CRChristine E. Ryan
Christine E. Ryan
RZRebecca Zon
Rebecca Zon
NINicolas Issa
Nicolas Issa

10 March 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJean-Maxime Côté
Jean-Maxime Côté
MDMichaël Desjardins
Michaël Desjardins
JCJean-François Cailhier
Jean-François Cailhier
PMPatrick T. Murray
Patrick T. Murray
WSWilliam Beaubien Souligny
William Beaubien Souligny
An increased risk of acute kidney injury (AKI) with the widely prescribed piperacillin-tazobactam(PTZ)-vancomycin combination in hospitalized patients has recently been reported, but evidence in ICU patients remain uncertain. This study evaluates the association between the exposure of various broad-spectrum antibiotic regimens with Pseudomonas and/or methicillin-resistance Staphylococcus aureus (MRSA) coverage and the risk of AKI in critically ill patients. A retrospective cohort study based on the publicly available MIMIC-III database reporting hospitalization data from ICU patients from a large academic medical center between 2001 and 2012. Adult patients receiving an anti-pseudomonal or an anti-MRSA agent in the ICU for more than 24-hours were included. Non-PTZ anti-pseudomonal agents were compared to PTZ; non-vancomycin agents covering MRSA were compared to vancomycin; and their combinations were compared to the PTZ-vancomycin combination. The primary outcome was defined as new or worsening AKI within 7 days of the antibiotic exposure using an adjusted binomial generalized estimating equation. Overall, 18 510 admissions from 15 673 individual patients, cumulating 169 966 days of antibiotherapy were included. When compared to PTZ, exposure to another anti-pseudomonal agent was associated with lower AKI risk (OR, 0.85; 95% CI, 0.80–0.91; p < .001). When compared to vancomycin, exposure to another anti-MRSA was also associated with lower AKI risk (OR, 0.71; 95% CI, 0.64–0.80; p < .001). Finally, when compared to the PTZ-vancomycin combination, exposure to another regimen with a similar coverage was associated with an even lower risk (OR, 0.63; 95% CI; 0.54–0.73; p < .001). A sensitivity analysis of patients with high illness severity showed similar results. These results suggest that the risk of AKI in ICU patients requiring antibiotherapy may be partially mitigated by the choice of antibiotics administered. Further clinical trials are required to confirm these findings.